SCHEMBL217093

SCHEMBL217093

COc1ccccc1N1CC[N]CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.66
DRD3 P35462 3/20 0.66
CYP2C19 P33261 2/20 0.64
HTR3E A5X5Y0 1/20 0.64
HTR3B O95264 1/20 0.64
ADRB1 P08588 1/20 0.64
HTR3A P46098 1/20 0.64
HTR6 P50406 1/20 0.64
HTR3D Q70Z44 1/20 0.64
HTR3C Q8WXA8 1/20 0.64
SIGMAR1 Q99720 1/20 0.64
LMNA P02545 3/20 0.62
MAPT P10636 3/20 0.62
ALDH1A1 P00352 4/20 0.56
HPGD P15428 1/20 0.56
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
USP2 O75604 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30407688 0.82 DRD2 (0.72) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL3165674 0.82 DRD2 (0.72) DRD2DRD3CYP2C19HTR3EHTR3B
Hydrochloric Acid SCHEMBL26690632 0.81 MAPT (0.71) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL3020451 0.81 DRD2 (0.70) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL3174809 0.81 DRD2 (0.70) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL219349 0.81 ALDH1A1 (0.61) DRD2DRD3MAPTALDH1A1L3MBTL1
SCHEMBL5812682 0.81 ADRA1A (0.56) ADRA1DADRA1AADRA1BHTR1A
SCHEMBL9526010 0.81 DRD2 (0.56) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL327835 0.79 DRD2 (1.00) DRD2DRD3CYP2C19HTR3EHTR3B
SCHEMBL1267564 0.79 DRD2 (0.68) DRD2DRD3CYP2C19HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117946031-A Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors 北京大学 2024-04-30 CN claimed
CN-117396465-A Novel oxazole derivative for preventing or treating allergic diseases and pharmaceutical composition containing the same 阿斯克里斯有限公司 2024-01-12 CN claimed
CN-110337293-A Therapeutic compound 新泽西鲁特格斯州立大学 2019-10-15 CN claimed
US-20190070149-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. 2019-03-07 US claimed
US-9663464-B2 Carbazole derivatives acting on 5-HT7 receptor KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2017-05-30 US claimed
US-20160244408-A1 CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2016-08-25 US claimed
US-9328107-B2 Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2016-05-03 US claimed
US-20160009752-A1 PREGNANE-OXIMINO-AMINOALKYLETHERS AND PROCESS FOR PREPARATION THEREOF, USEFUL AS ANTIDIABETIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-01-14 US claimed
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2015-07-16 US claimed
US-8981131-B2 Tricyclic compounds for the treatment of inflammatory disorders Piramal Enterprises Limited (IN) 2015-03-17 US claimed
US-5403842-A Adrenergic blocking and antiserotonine agents; urogenital disorders including spasms of the urethral tract and prostrate problems RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) 1995-04-04 US claimed
EP-0611748-A1 Propanolamine derivatives and their use as hypotensive or antiglaucoma agents Senju Pharmaceutical Co., Ltd. (JP) 1994-08-24 EP claimed
EP-0374054-B1 INDANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES OBTAINED, THEIR USE AS MEDICINES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1993-10-06 EP claimed
WO-1993017007-A1 HETEROBICYCLIC COMPOUNDS RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) 1993-09-02 WO claimed
EP-0558245-A1 Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) 1993-09-01 EP claimed
EP-0120770-B1 2-AMINOETHYL PYRIDINE OR PYRAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIOM LABORATOIRES- C.E.R.M. "R.L.-CERM" - (S.A.) (FR) 1988-03-23 EP claimed
EP-0110781-B1 SUBSTITUTED (AMINO-2-ETHYL)-6-BENZOXAZOLINONES, THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM RIOM LABORATOIRES- C.E.R.M. (Société Anonyme) (FR) 1987-04-01 EP claimed
US-4556656-A HYPOTENSIVE, ANTIPSYCHOTIC, DIABETIC, AND ANALGESIC AGENTS THE UPJOHN COMPANY (US) 1985-12-03 US claimed
EP-0120770-A1 2-Aminoethyl pyridine or pyrazine derivatives, their preparation and pharmaceutical compositions containing them RIOM LABORATOIRES- C.E.R.M. "R.L.-CERM" - (S.A.) (FR) 1984-10-03 EP claimed
EP-0049203-A1 Benzoxazolinones substituted in the 6-position by an amino-alcohol or amino-ketone chain, their preparation and their therapeutic use RIOM LABORATOIRES- C.E.R.M. (Société Anonyme) (FR) 1982-04-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190070149-A1 PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO HTR5A, HTR2A, HTR1A DRD2 114/4885DRD3 490/4885CYP2C19 141/4885
US-20160009752-A1 PREGNANE-OXIMINO-AMINOALKYLETHERS AND PROCESS FOR PREPARATION THEREOF, USEFUL AS ANTIDIABETIC AND ANTIDYSLIPIDEMIC AGENTS CYP3A43, CYP11B1, CYP11B2 DRD2 2197/4885DRD3 605/4885CYP2C19 64/4885
US-20150197492-A1 NOVEL INDENO[1,2-c]QUINOLIN-11-ONE DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF TOP1, TOP2A, TOP2B DRD2 3616/4885DRD3 3271/4885CYP2C19 307/4885
US-20160244408-A1 CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR HTR7, HTR3A, HTR3B DRD2 220/4885DRD3 182/4885CYP2C19 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.